Clinical trial NCT05795049: Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity
Official title: Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity Mechanism and Guide Personalised Treatment Using a Non-invasive Multiparametric Test (Work Package 1)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Irritable Bowel Syndrome (IBS)
Sucrase Isomaltase Deficiency
Keywords: nutrigenetics
carbohydrates maldigestion
Lead sponsor: Nottingham University Hospitals NHS Trust
Sponsor class: OTHER
Collaborators: name: CICbioGUNE
name: Christian-Albrechts-University of Kiel
name: University of Veterinary Medicine Hannover
First posted: 2023-04-03
Enrollment: 2000
Sex: ALL
Minimum age (years): 5
Maximum age (years): 70
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Multicentre study. IBS patients identified through secondary and tertiary care gastroenterological clinics.

Asymptomatic adult controls recruited at the same site as respective patients or, for instance, from transfusion clinics, blood donor centres, bowel cancer screening as long as data on the absence of symptoms is documented.

Brief summary: Irritable bowel syndrome (IBS) affects one in seven people with gastrointestinal (GI) symptoms. IBS strongly impacts quality of life, is a leading cause of work absenteeism, and consumes 0.5% of the healthcare annual budget. It manifests in women more than men with symptoms including abdominal pain, bloating, constipation (IBS-C), diarrhoea (IBS-D), and mixed presentations (IBS-M) (1). The development of therapeutic options is hampered by the poor understanding of the underlying cause of symptoms.

Many patients find that certain foods (particularly carbohydrates) trigger their symptoms, and avoiding such foods has been shown effective in IBS, like in the low-FODMAP (fermentable oligo-, di-, mono-saccharides and polyols) exclusion diet.

This has suggested that the food-symptom relation may involve malabsorption of carbohydrates due to inefficient digestion. However only a percentage of patients respond to this diet. Recently it has been reported that a subset of IBS carries hypomorphic (defective) gene variant of the sucrase isomaltase (SI), the enzyme that normally digests carbohydrates, sucrose and starch. This carbohydrate maldigestion (the breakdown of complex carbohydrates by a person's small bowel enzymes) is characterized by diarrhoea, abdominal pain and bloating, which are also features of IBS. This possibly occurs via accumulation of undigested carbohydrates in the large bowel, where they cause symptoms due to gas production following bacterial fermentation. Similar mechanisms may be acting at the level of other enzymes involved in the digestion, breakdown and absorption of carbohydrates (carb digestion genes -CDGs). Aim of the study is to study the prevalence of this genetic alteration in a large number of IBS patients as compared to asymptomatic controls.


Eligibility criteria: Inclusion Criteria for Patients:

* Patients age between 5 and 70 years of age.
* Patients with IBS-D or IBS-M as defined by the Rome III criteria.
* Previous negative endoscopy with biopsies excluding IBD or microscopic colitis in patients above 50 years old
* Negative relevant additional screening or consultation whenever appropriate
* Ability to conform to the study protocol

Exclusion Criteria for Patients:

* Patients with IBS-C or IBS-U according to Rome III criteria
* Patients with any condition which, in the opinion of the investigator, makes the patient unsuitable for participation in the study.
* Patients on opioids
* Patients with concurrent organic gastrointestinal disease (inflammatory bowel disease, celiac disease, cancer), or a major disease such as diabetes, uncontrolled thyroid disease
* Patients with a history of bowel surgery (not appendectomy or cholecystectomy)
* Concurrent major confounding condition, e.g. alcohol or substance abuse in the last 2 years (clinician's judgement).

Inclusion Criteria for healthy controls:

* Between 5 and 70 years of age
* Absence of Rome III IBS criteria

Exclusion Criteria for healthy controls:

* Blood relatives of the participating IBS patient are not allowed to participate.
* Person with any condition which, in the opinion of the investigator, makes them unsuitable for participation in the study.
* Person presenting with a functional or organic GI disorder.
* Person presenting with underlying disease that may involve the GI tract (e.g. Parkinson's disease) or be associated with GI symptoms (e.g. anorexia nervosa, major depression).

Primary outcomes:
measure: number of IBS-D and IBS-M with of SI and CDG hypomorphic variants as compared to asymptomatic controls
timeFrame: baseline
Secondary outcomes:
measure: Difference in age between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in gender between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in ethnicity between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in IBS subtype between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in post-infectious onset between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in number of previous abdominal surgery between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in symptoms presentations between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in anxiety and depression between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in somatisation between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in habitual intake of sugars between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in quality of life between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in symptoms between patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in anxiety and depression between paediatric patients carriers and non-carriers of defective (hypomorphic) gene
timeFrame: baseline
measure: Difference in in vitro SI enzyme activity in human cells with defective gene as compare with those with normal gene
timeFrame: baseline
Other outcomes:
Locations:
city: Nottingham
country: United Kingdom
facility: Nottingham University Hospitals NHS Trust
Study officials:
References:
citation: Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017 Jun 29;376(26):2566-2578. doi: 10.1056/NEJMra1607547. No abstract available.
citation: Shepherd SJ, Lomer MC, Gibson PR. Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol. 2013 May;108(5):707-17. doi: 10.1038/ajg.2013.96. Epub 2013 Apr 16.
citation: Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016 Dec;111(12):1824-1832. doi: 10.1038/ajg.2016.434. Epub 2016 Oct 11.
citation: Ament ME, Perera DR, Esther LJ. Sucrase-isomaltase deficiency-a frequently misdiagnosed disease. J Pediatr. 1973 Nov;83(5):721-7. doi: 10.1016/s0022-3476(73)80362-2. No abstract available.
citation: Chumpitazi BP, Lewis J, Cooper D, D'Amato M, Lim J, Gupta S, Miranda A, Terry N, Mehta D, Scheimann A, O'Gorman M, Tipnis N, Davies Y, Friedlander J, Smith H, Punati J, Khlevner J, Setty M, Di Lorenzo C. Hypomorphic SI genetic variants are associated with childhood chronic loose stools. PLoS One. 2020 May 20;15(5):e0231891. doi: 10.1371/journal.pone.0231891. eCollection 2020.
citation: Henstrom M, Diekmann L, Bonfiglio F, Hadizadeh F, Kuech EM, von Kockritz-Blickwede M, Thingholm LB, Zheng T, Assadi G, Dierks C, Heine M, Philipp U, Distl O, Money ME, Belheouane M, Heinsen FA, Rafter J, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Walter S, Simren M, Karling P, Ohlsson B, Schmidt PT, Lindberg G, Dlugosz A, Agreus L, Andreasson A, Mayer E, Baines JF, Engstrand L, Portincasa P, Bellini M, Stanghellini V, Barbara G, Chang L, Camilleri M, Franke A, Naim HY, D'Amato M. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut. 2018 Feb;67(2):263-270. doi: 10.1136/gutjnl-2016-312456. Epub 2016 Nov 21.
citation: Garcia-Etxebarria K, Zheng T, Bonfiglio F, Bujanda L, Dlugosz A, Lindberg G, Schmidt PT, Karling P, Ohlsson B, Simren M, Walter S, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Portincasa P, Bellini M, Barbara G, Jonkers D, Eswaran S, Chey WD, Kashyap P, Chang L, Mayer EA, Wouters MM, Boeckxstaens G, Camilleri M, Franke A, D'Amato M. Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1673-1676. doi: 10.1016/j.cgh.2018.01.047. Epub 2018 Feb 21.
citation: Thingholm L, Ruhlemann M, Wang J, Hubenthal M, Lieb W, Laudes M, Franke A, D'Amato M. Sucrase-isomaltase 15Phe IBS risk variant in relation to dietary carbohydrates and faecal microbiota composition. Gut. 2019 Jan;68(1):177-178. doi: 10.1136/gutjnl-2017-315841. Epub 2018 Jan 13. No abstract available.
citation: Husein DM, Naim HY. Impaired cell surface expression and digestive function of sucrase-isomaltase gene variants are associated with reduced efficacy of low FODMAPs diet in patients with IBS-D. Gut. 2020 Aug;69(8):1538-1539. doi: 10.1136/gutjnl-2019-319411. Epub 2019 Jul 22. No abstract available.
citation: Zheng T, Eswaran S, Photenhauer AL, Merchant JL, Chey WD, D'Amato M. Reduced efficacy of low FODMAPs diet in patients with IBS-D carrying sucrase-isomaltase (SI) hypomorphic variants. Gut. 2020 Feb;69(2):397-398. doi: 10.1136/gutjnl-2018-318036. Epub 2019 Jan 18. No abstract available.
citation: Spiller RC, Thompson WG. Bowel disorders. Am J Gastroenterol. 2010 Apr;105(4):775-85. doi: 10.1038/ajg.2010.69. No abstract available.
citation: Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, Walker LS. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology. 2006 Apr;130(5):1527-37. doi: 10.1053/j.gastro.2005.08.063.
citation: Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997 Apr;11(2):395-402. doi: 10.1046/j.1365-2036.1997.142318000.x.
citation: Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003 Aug 1;1:29. doi: 10.1186/1477-7525-1-29.
citation: Spiller RC, Humes DJ, Campbell E, Hastings M, Neal KR, Dukes GE, Whorwell PJ. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther. 2010 Sep;32(6):811-20. doi: 10.1111/j.1365-2036.2010.04402.x.
citation: Varni JW, Bendo CB, Denham J, Shulman RJ, Self MM, Neigut DA, Nurko S, Patel AS, Franciosi JP, Saps M, Verga B, Smith A, Yeckes A, Heinz N, Langseder A, Saeed S, Zacur GM, Pohl JF. PedsQL gastrointestinal symptoms module: feasibility, reliability, and validity. J Pediatr Gastroenterol Nutr. 2014 Sep;59(3):347-55. doi: 10.1097/MPG.0000000000000414.
citation: Irwin DE, Stucky B, Langer MM, Thissen D, Dewitt EM, Lai JS, Varni JW, Yeatts K, DeWalt DA. An item response analysis of the pediatric PROMIS anxiety and depressive symptoms scales. Qual Life Res. 2010 May;19(4):595-607. doi: 10.1007/s11136-010-9619-3. Epub 2010 Mar 7.